We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · October 10, 2022

Adjuvant Nivolumab Plus Ipilimumab vs Nivolumab Alone in Patients With Resected Stage IIIB–D/IV Melanoma

Journal of Clinical Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
J. Clin. Oncol 2022 Sep 26;[EPub Ahead of Print], JS Weber, D Schadendorf, M Del Vecchio, J Larkin, V Atkinson, M Schenker, J Pigozzo, H Gogas, S Dalle, N Meyer, PA Ascierto, S Sandhu, T Eigentler, R Gutzmer, JC Hassel, C Robert, MS Carlino, AM Di Giacomo, MO Butler, E Muñoz-Couselo, MP Brown, P Rutkowski, A Haydon, JJ Grob, J Schachter, P Queirolo, L de la Cruz-Merino, A van der Westhuizen, AM Menzies, S Re, T Bas, V de Pril, J Braverman, DJ Tenney, H Tang, GV Long

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading